BioSpace News Archive

Melinta Therapeutics, LLC, a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses, is partnering with OptimizeRx Corp. in an Innovate4Outcomes event - a healthcare design thinking-inspired event.

First Wave BioPharma, Inc. announced today that it has submitted an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (FDA) to evaluate an enhanced enteric microgranule delivery formulation of adrulipase as a treatment for exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP) in human clinical trials.

Tonix Pharmaceuticals Holding Corp. today announced data from its fully human anti-SARS-CoV-2 monoclonal antibody platform in an oral presentation delivered by Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, at the World Antiviral Congress 2022 in San Diego, Calif.

Aileron Therapeutics today announced that it received written notice on November 28, 2022 from The Nasdaq Stock Market noting that Aileron has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2), which requires the company to maintain a minimum closing bid price of $1.00 per share.

BioXcel Therapeutics, Inc. today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, orally dissolving film, for agitation associated with bipolar I or II disorder or schizophrenia.

AnPac Bio-Medical Science Co., Ltd. today announced that the company has been notified by the Office of the General Counsel of The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1 per share bid price requirement of Listed Securities required for continued listing as set forth in Listing Rule 5450(a)(1).

Kira Pharmaceuticals today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients in China.

Renalytix plc today reported financial results for the fiscal first quarter ended September 30, 2022.

PureTech Health plc today announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTech’s Glyph™ platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Q4 of 2023.

The Addario Lung Cancer Medical Institute (ALCMI), a patient-founded not-for-profit global research consortium, has launched the SPARK Study to help researchers better understand treatment resistance in patients with KRAS-positive lung cancer and other cancer types.